FLT

The fms-like tyrosine kinase (Fit) is a transmembrane receptor in the tyrosine kinase family. Expression of fit complementary DNA in COS cells conferred specific, high-affinity binding of vascular endothelial growth factor, also known as vascular permeability factor (VEGF-VPF).

Cat. No.	Product name	CAS No.	Purity
T6289	Dovitinib	405169-16-6	99.78%
T6289	Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) an...
T2500	Cediranib	288383-20-0	99.78%
T2500	Cediranib (AZD2171) (AZD2171) is a highly potent (IC50 < 1 nmol/L) ATP-competitive inhibitor of recombinant KDR tyrosine kinase in vitro, also inhibits Flt1/4 (I...
T22012	7BIO	916440-85-2	99.77%
T22012	7-bromoindirubin-3'-oxime (7BIO) is a caspase independent nonapoptotic cell death inducer. 7BIO is an inhibitor of FLT3, DYRK1A, DYRK2, Aurora B and Aurora C kin...
T2624	OSI-930	728033-96-3	99.76%
T2624	OSI-930, an orally active inhibitor of c-Kit and the vascular endothelial growth factor receptor-2 (VEGFR-2), targets cancer cell proliferation and blood vessel ...
T1667	Tandutinib	387867-13-2	99.74%
T1667	Tandutinib (CT53518) (MLN518, CT53518), an effective FLT3 antagonist (IC50: 0.22 μM), can also inhibit c-Kit and PDGFR, 15-20 fold higher potency for FLT3 versus...
T4349	Sitravatinib	1123837-84-2	99.74%
T4349	Sitravatinib (MGCD516) (MGCD516) is an inhibitor targeting multiple RTKs involved in driving sarcoma cell growth, including c-Met, c-Kit, PDGFRα/β, PDGFR, and Ax...
T7007	UNC2025	1429881-91-3	99.74%
T7007	UNC2025 (mrx-6313)(IC50 of 0.74 nM and 0.8 nM) is a potent and orally bioavailable dual MER/FLT3 inhibitor. UNC-2025 is about 20-fold selectivity higher than Axl...
T9473	4SC-203	895533-09-2	99.73%
T9473	4SC-203 is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated f...
T8482	Ripretinib	1442472-39-0	99.72%
T8482	Ripretinib (DCC-2618) is an orally bioavailable inhibitor of KIT and PDGFRA.
T4409	Gilteritinib	1254053-43-4	99.72%
T4409	Gilteritinib (ASP2215) is a potent inhibitor at the FMS-related tyrosine kinase 3 (FLT3) and AXL tyrosine kinase receptors (IC50 = 0.29 nM and <1 nM, respectivel...
T4419	UNC2025 2HCl (1429881-91-3(free base))	T4419	99.71%
T4419	UNC2025 is a potent and orally bioavailable Mer/Flt3 dual inhibitor with IC50 of 0.8/0.74 nM for Mer/Flt3.
T8326	BMS-2	888719-03-7	99.7%
T8326	BMS-2 is a Met/Flt-3/VEGFR2 tyrosine kinase inhibitor.
T71857	GTP-14564	34823-86-4	99.69%
T71857	GTP-14564 is a novel tyrosine kinase inhibitor that also inhibits wt-FLT3 and ITD-FLT3. GTP-14564 inhibits the growth of interleukin-3-independent Ba/F1 expressi...
T6711	Tyrphostin AG1296	146535-11-7	99.68%
T6711	Tyrphostin AG1296 (Tyrphostin AG 1296) is an inhibitor of PDGFR with IC50 of 0.3-0.5 μM, no activity to EGFR.
T3166	VX-11e	896720-20-0	99.67%
T3166	VX-11e (TCS ERK 11e) is a potent, selective, and orally bioavailable ERK(Extracellular Signal-Regulated Kinase) inhibitor; antitumor agent.
T2115	Pexidartinib	1029044-16-3	99.66%
T2115	Pexidartinib (PLX-3397) is a capsule formulation containing a small-molecule receptor tyrosine kinase (RTK) inhibitor of KIT, CSF1R and FLT3 with potential antin...
T4209	TAK-659 hydrochloride	1952251-28-3	99.63%
T4209	TAK-659 hydrochloride (TAK-659) is a potent and selective inhibitor of spleen tyrosine kinase (SYK) with an IC50 value of 3.2 nM. It is selective against most ot...
T9017	HPK1-IN-2	2056122-11-1	99.62%
T9017	HPK1-IN-2 (Thieno[2,3-b]pyridin-6(7H)-one, 4-amino-5-[6-(4-methyl-1-piperazinyl)-1H-benzimidazol-2-yl]-HPK1-IN-2) is a potent and orally active inhibitor of hema...
T9027	CA-4948	1801344-14-8	99.62%
T9027	CA-4948 (Emavusertib) is a potent IRAK4/FLT3 inhibtor. CA-4948 with anti-tumor activity.
T0093L	Sorafenib	284461-73-0	99.61%
T0093L	Sorafenib (Bay 43-9006) is a multikinase inhibitor that inhibits Raf-1, B-Raf, VEGFR2, VEGFR3, VEGFR4, PDGFRβ, FLT3, c-Kit, and others (IC50=6/22/90/15/20/20/57/...